Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher

Compared to Standard Chemotherapy

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised. Seventy-four percent of patients discontinued therapy for disease progression or death, the majority of which were in the standard chemotherapy control arm.

CTI plans to submit complete study data for presentation at a major scientific conference. CTI also intends to request a pre-NDA meeting with the FDA and expects to begin submission of a rolling New Drug Application (NDA) to the FDA in early 2009.

"This positive phase II
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Dompe, a leader in R&D for new ... rhNGF (Recombinant Human Nerve Growth Factor) has been designated as ... (FDA). The candidate drug, developed by the ... for the treatment of neurotrophic keratitis, a degenerative corneal disease ... and is currently without a cure. This is the second ...
(Date:7/23/2014)... 2014 Research and Markets ... Medical Kits and Trays - Global Strategic Business ... http://photos.prnewswire.com/prnh/20130307/600769 This ... Kits and Trays in US$ Thousands by the ... Trays, Custom Basin Kits, Custom Ob/Gyn Kits, General ...
(Date:7/23/2014)... 2014  ArmaGen, a privately held biotechnology company ... neurological disorders, announced today that it has entered ... Shire plc to develop AGT-182, an investigational enzyme ... the central nervous system (CNS) and somatic (body-related) ... II, Hunter syndrome is a rare, severe, progressive ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3
(Date:7/23/2014)... 23, 2014 The discounts that some ... products do not include various skin creams or oil ... skin tightening cream discounts inside of its cost saving ... is now available to offer a direct source for ... products available for sale. Although the guide includes pricing, ...
(Date:7/23/2014)... Men and women who are married ... insurance based on national averages. The Quotes Pros company ... to its comprehensive tool this year to help married ... , Providers that are now underwriting plans on a ... one or two clicks. The intelligent platform used to ...
(Date:7/23/2014)... July 23, 2014 The puffiness that ... using non-surgical techniques, according to a new guide published ... serum sold in the U.S. is now available for ... , The complimentary guide that is now published is ... with under eye puffiness. While surgical techniques are available, ...
(Date:7/23/2014)... 2014 Recently, iFitDress.com, a professional company of ... of 2014 vintage party dresses . Aside from that, ... current discount is up to 63% off. , “We are ... These new items are all manufactured by trustworthy and experienced ... until July 30; it is great to provide such a ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
Breaking Medicine News(10 mins):Health News:Skin Tightening Cream Discounts Revealed in New Cost Saving Guide at Consumer Portal 2Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3
... embryos or adult mice to behave like stem cells ... in an immediate early publication of the journal Cell. ... stem cells" (iPS) behaved physically and genetically as stem ... used to treat a host of diseases, such as ...
... a ban on Coke and Pepsi by the Kerala Government, the ... forth a proposal to stop the sale// and production of 11 ... ,Top brass in the companies are very unhappy over these moves, ... company which is not in sync with the reports from ...
... has called for moratoriums on consumer advertising which promotes ... that the products// are safe and that they work. ... group has urged the U.S. Food and Drug Administration ... after a drug or device obtains regulatory approval before ...
... found in a study that instead of dieting, which could ... and thereby a desire// to change it, women who accept ... lowest body mass index (BMI). ,The researchers have ... disorders. Tracy Tylka, assistant professor of psychology and one of ...
... is a rare condition that affects children as well ... named anakinra could alleviate// symptoms and bring down the ... in the August 10 issue of the New England ... Research Program of the National Institute of Arthritis and ...
... a sharp rise in polio cases in the country with ... as against a total of 66 last year.// ... upper house, Friday that the transmission of poliovirus may continue ... target". ,In a written answer he said that ...
Cached Medicine News:Health News:Only A Few Differentiating Factors Between Adult And Stem Cells 2Health News:Drug Advertising needs to be Limited 2Health News:Study Finds Healthier Women Are Those Who Accept The Way They Look 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
... Model 3085 temporary pacemaker is designed to ... for temporary atrial or ventricular or A-V ... where such pacing modes are indicated for ... Model 3085 can be used to measure ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... system provides an ideal solution for ... laboratory, satellite lab and the clinic ... method with wedge-smear technology, the ADVIA ... in a safe enclosed environment. The ...
... T600 treadmill has streamlined design, ... a brushless DC motor and ... unique system that operates on ... in smooth operation, remarkably low ...
Medicine Products: